Resultats de la cerca - Kenji Hashimoto

Refinar resultats
  1. 1
    Brain‐derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions

    Brain‐derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions per Kenji Hashimoto

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker

    Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker per Kenji Hashimoto

    Publicat 2015
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Tropisetron and its targets in Alzheimer’s disease

    Tropisetron and its targets in Alzheimer’s disease per Kenji Hashimoto

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Editorial
    Afegir a favorits
    Guardat en:
  4. 4
    Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication

    Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication per Kenji Hashimoto

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Inflammatory Biomarkers as Differential Predictors of Antidepressant Response

    Inflammatory Biomarkers as Differential Predictors of Antidepressant Response per Kenji Hashimoto

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Letter to the Editor:<i>R</i>-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity

    Letter to the Editor:<i>R</i>-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity per Kenji Hashimoto

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  7. 7
    Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective

    Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective per Kenji Hashimoto

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders

    Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders per Kenji Hashimoto

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

    Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective per Kenji Hashimoto

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

    Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine per Kenji Hashimoto

    Publicat 2020
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

    Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor per Kenji Hashimoto

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development

    CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development per Kenji Hashimoto

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  13. 13
    Arketamine for cognitive impairment in psychiatric disorders

    Arketamine for cognitive impairment in psychiatric disorders per Kenji Hashimoto

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  14. 14
    Overview of the potential use of fluvoxamine for COVID-19 and long COVID

    Overview of the potential use of fluvoxamine for COVID-19 and long COVID per Kenji Hashimoto

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  15. 15
    Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis

    Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis per Kenji Hashimoto

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions

    Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions per Kenji Hashimoto

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  17. 17
    Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?

    Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? per Kenji Hashimoto

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease

    α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease per Jun Toyohara, Kenji Hashimoto

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP3 Receptors

    Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP3 Receptors per Tamaki Ishima, Kenji Hashimoto

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine

    Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine per Yukihiko Shirayama, Kenji Hashimoto

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: